harmaline has been researched along with bufotenin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, XL; Shen, HW; Wu, C; Yu, AM | 1 |
| Jiang, XL; Shen, HW; Winter, JC; Yu, AM | 1 |
1 review(s) available for harmaline and bufotenin
| Article | Year |
|---|---|
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Topics: Animals; Bufotenin; Cytochrome P-450 CYP2D6; Drug Interactions; Hallucinogens; Harmaline; Humans; Methoxydimethyltryptamines; Pharmacogenetics; Serotonin Receptor Agonists | 2010 |
1 other study(ies) available for harmaline and bufotenin
| Article | Year |
|---|---|
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Topics: Animals; Area Under Curve; Bufotenin; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Genotype; Half-Life; Harmaline; Hepatocytes; Humans; Isoenzymes; Kinetics; Methoxydimethyltryptamines; Methylation; Mice; Mice, Transgenic; Microsomes, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenotype; Polymorphism, Genetic; Psychotropic Drugs | 2010 |